Falipamil
Names | |
---|---|
Preferred IUPAC name
2-(3-{[2-(3,4-Dimethoxyphenyl)ethyl]methylamino}propyl)-5,6-dimethoxy-2,3-dihydro-1H-isoindol-1-one | |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C24H32N2O5 | |
Molar mass | 428.52128 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Falipamil is a calcium channel blocker.[1]
Research
Falipamil is a
Falipamil has different effects on the electrophysiological structure of the heart, where different dosages result in different heart activity rates with diverse vagolytic actions. Recent studies have been carried out on dogs to determine the effectiveness of the drug in treating sinuses. When administered to a conscious dog, the sinus heart rate of the dog increases, whereas when administered to a stale dog, the animal experiences a lessened heart rate.[2] The electrophysiological result of administering falipamil shows that the drug decreases the maximal atrial driving frequency when administered to a conscious dog, which is an effective measure in reducing sinus in a living organism. Falipamil administration also shows that the administration of the drug increases the body's action potential exerting less bradycardic effects that are effective in reducing sinuses. Fallipamil does have different recovery times when administered to dogs involved in different activities. Intact dogs are likely to have short sinus recovery time-conscious dogs.[2] Falipamil has a positive effect on the heart's refractory period, where the drug prolongs the atrial refractory period.
References
- ISBN 9783642736667.
- ^ PMID 8813620.